CTLA4 and cancer: Research has furthermore discovered that the occurrence of hyperthyroidism and hypothyroidism in individuals with cancer who use PD-1 inhibitors is significantly higher compared to those who receive CTLA-4 inhibitors or PD-L1 inhibitors alone (100), suggesting that immune imbalance caused by PD-1 abnormalities may play an essential role in TED.